Clinical Development and Marketed Products
TB Alliance manages the largest pipeline of new TB drugs in history and has advanced multiple products to market. Projects with the potential to have the greatest impact on the disease, while being cost-effective and simple to administer, are prioritized. Our pipeline is updated on a quarterly basis. For the latest status of our trials, please visit clinicaltrials.gov or contact us to schedule a briefing.
TBA-7371 / DprE1 Inhibitor